A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: The VOYAGER study

British Journal of Ophthalmology

Volumn 99, Issue 6, 2015, Pages 738-745

  Weinreb, Robert N ^a   Ong, Tuyen ^b   Sforzolini, Baldo Scassellati ^b   Vittitow, Jason L ^b   Singh, Kuldev ^c   Kaufman, Paul L ^d   Ackerman, S ^e   Branch, J ^e   Cottingham, A ^e   Day, D ^e   Depenbusch, M ^f   El Hazari, S ^e   Firozvi, A ^e   Jorizzo, P ^e   Ou, R ^e   Peace, J ^e   Rotberg, M ^e   Schenker, H ^e   Smith, S ^e   Tyson, F ^e   Zaman, F ^e   Madzharova, L ^e   Toshev, R ^g   Vassilveva, P ^e   Misiuk Hojlo M ^e   Kociecki J ^e   Liehneova, I ^h   Ruzickova E ^e   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAUSCH AND LOMB   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e NONE   (Czech Republic)

^f NONE   (United States)

^g NONE   (United Kingdom)

^h Hospital of Masaryk Ustinad Labem   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; LATANOPROSTENE BUNOD; ANTIHYPERTENSIVE AGENT; BOL 303259-X; EYE DROPS; PROSTAGLANDIN F;

ABNORMAL SENSATION; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EYE IRRITATION; EYE PAIN; FEMALE; FOLLOW UP; HUMAN; INSTILLATION SITE PAIN; INSTILLATION SITE PRURITUS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PHYSIOLOGY; VERY ELDERLY; VISUAL ACUITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR; VISUAL ACUITY; YOUNG ADULT;

EID: 84930373569     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305908     Document Type: Article

References (24)

1. Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2009;50:1497-505.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20.
3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311:1901-11.
4. Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004;138:458-67.
5. Challa P, Arnold JJ. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opin Investig Drugs 2014;23:81-95.
6. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56.
7. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
8. Galbelt BT, Kaufman PL. Production and flow of aqueous humor. In: Levin LA, Nilsson SFE, Ver Hoeve J, Wu SM, Alm A, Kaufman PL., eds. Adler's physiology of the eye. 11th edn. St Louis: Mosby Elsevier, 274-307.
9. Kass M.A, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a raondmized trial determines that topical hypotensive medication dealys or prevents the onset of primary open angle glaucoma. Arch Ophthalmol 2002;120:701-3.
10. Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol 2013;97:196-200.
11. Digiuni M, Manni G, Vetrugno M, et al. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 2013;22:707-12.
12. Allaire C, Dietrich A, Allmeier H, et al. Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma. Eur J Ophthalmol 2012;22:19-27.
13. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res 2011;93:250-5.
14. Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 1995;36:1774-84.
15. Gabelt BT, Kaufman PL, Rasmussen CA. Effect of nitric oxide compounds on monkey ciliary muscle in vitro. Exp Eye Res 2011;93:321-7.
16. Heyne GW, Kiland JA, Kaufman PL, et al. Effect of nitric oxide on anterior segment physiology in monkeys. Invest Ophthalmol Vis Sci 2013;54:5103-10.
17. Cavet ME, Vittetow JL, Impagnatiello F, et al. Nitric oxide (NO): An emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci 2014;55:5005-15.
18. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol 2008;294:C1378-86.
19. Dismuke WM, Ellis DZ. Activation of the BK(Ca) channel increases outflow facility and decreases trabecular meshwork cell volume. J Ocul Pharmacol Ther 2009;25:309-14.
20. Kaufman PL, Rasmussen CA. Advances in glaucoma treatment and management: outflow drugs. Invest Ophthalmol Vis Sci 2012;53:2495-500.
21. Stamer WD, Lei Y, Boussommier-Calleja A, et al. eNOS, a pressure-dependent regulator of intraocular pressure. Invest Ophthalmol Vis Sci 2011;52:9438-44.
22. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304.
23. Summary of Product Characteristics Xalatan 0,005% eye drops solution, Pharmacia Ltd, UK 2007. http://www.medicines.org.uk/emc/medicine/9043/SPC/ (accessed 24 Jul 2014).
24. Eveleth D, Starita C, Tressler C. A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension. BMC Ophthalmol 2012;12:9.